Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The disposition of debrisoquine in hypertensive patients.

Literature DB >> 619932

The disposition of debrisoquine in hypertensive patients.

J H Silas, M S Lennard, G T Tucker, A J Smith, S L Malcolm, T R Marten.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Isoquinolines
Debrisoquin

Year: 1978 PMID： 619932 PMCID： PMC1429235 DOI： 10.1111/j.1365-2125.1978.tb01594.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

9 in total

1. Letter: Debrisoquine, guanethidine, and bethanidine in hypertension.

Authors: S Talbot; B C O'Malley; R H Bing
Journal: Br Med J Date: 1975-05-03

2. The metabolism of debrisoquine in rat and man.

Authors: M Angelo; L G Dring; R Lancaster; R L Smith
Journal: Biochem Soc Trans Date: 1976 Impact factor: 5.407

3. Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry.

Authors: S L Malcolm; T R Marten
Journal: Anal Chem Date: 1976-05 Impact factor: 6.986

4. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.

Authors: J G Allen; P B East; R J Francis; J L Haigh
Journal: Drug Metab Dispos Date: 1975 Sep-Oct Impact factor: 3.922

5. Disposition of bethanidine, N-benzyl-N',N''-dimethylguanidine, in the rat, dog and man.

Authors: L B Turnbull; L Teng; J Newman; A N Chremos; R B Bruce
Journal: Drug Metab Dispos Date: 1976 May-Jun Impact factor: 3.922

6. The influence of debrisoquin on the accumulation and metabolism of biogenic amines by the human platelet, in vivo and in vitro.

Authors: H M Solomon; C Ashley; N Spirt; W B Abrams
Journal: Clin Pharmacol Ther Date: 1969 Mar-Apr Impact factor: 6.875

7. Why hypertensive patients vary in their response to oral debrisoquine.

Authors: J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal: Br Med J Date: 1977-02-12

8. Time-dependent change in renal clearance of bethanidine in humans.

Authors: A N Chremos; D Shen; M Gibaldi; J D Proctor; J H Newman
Journal: J Pharm Sci Date: 1976-01 Impact factor: 3.534

9. Pharmacokinetics of bethanidine in hypertensive patients.

Authors: D Shen; M Gibaldi; A Israili; G Bellward; R Cunningham; M Throne; P Dayton; J McNay
Journal: Clin Pharmacol Ther Date: 1975-03 Impact factor: 6.875

9 in total

11 in total

The disposition of debrisoquine in hypertensive patients.

1. Letter: Debrisoquine, guanethidine, and bethanidine in hypertension.

2. The metabolism of debrisoquine in rat and man.

3. Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry.

4. Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.

5. Disposition of bethanidine, N-benzyl-N',N''-dimethylguanidine, in the rat, dog and man.

6. The influence of debrisoquin on the accumulation and metabolism of biogenic amines by the human platelet, in vivo and in vitro.

7. Why hypertensive patients vary in their response to oral debrisoquine.

8. Time-dependent change in renal clearance of bethanidine in humans.

9. Pharmacokinetics of bethanidine in hypertensive patients.

1. Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Review 2. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

3. Genetically determined oxidation capacity and the disposition of debrisoquine.

Review 4. Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Review 5. Measurement of the renal clearance of drugs.

6. Drug resistance, inappropriate dosing and non-compliance in hypertensive patients.

7. Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone.

8. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.

9. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.

10. Debrisoquine oxidation polymorphism in a Tasmanian population.